A meta-analysis of three RCTs with 275 patients found that adding anti-EGFR therapy to CT significantly improved PFS in recurrent GBM compared to CT alone (HR 0.75, 95% CI 0.58–0.96; moderate-quality evidence, Class IV) (Figure 5) [53]. The gene discussed is EGFR; the disease is glioblastoma.